Eleven Biotherapeutics Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eleven Biotherapeutics (EBIO) Posts Smaller Q1 Loss
April 30, 2015 10:14 AM EDTBefore the open, Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.36), $0.11 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.
Cash and cash equivalents were $45.5 million as of March 31, 2015. "We believe that our... More
